10X GENOMICS INC-CLASS A (TXG)
US88025U1097 - Common Stock
We assign a fundamental rating of 4 out of 10 to TXG. TXG was compared to 56 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for TXG as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, TXG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TXG had negative earnings in the past year.
TXG had a positive operating cash flow in the past year.
TXG had negative earnings in each of the past 5 years.
In the past 5 years TXG reported 4 times negative operating cash flow.
1.2 Ratios
TXG has a Return On Assets of -19.47%. This is in the lower half of the industry: TXG underperforms 60.71% of its industry peers.
TXG has a Return On Equity of -25.26%. This is comparable to the rest of the industry: TXG outperforms 44.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.47% | ||
| ROE | -25.26% | ||
| ROIC | N/A |
ROA(3y)-16.09%
ROA(5y)-22.37%
ROE(3y)-20.72%
ROE(5y)-28.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 66.63%, TXG belongs to the top of the industry, outperforming 96.43% of the companies in the same industry.
TXG's Gross Margin has declined in the last couple of years.
TXG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.32%
GM growth 5Y-3.84%
2. Health
2.1 Basic Checks
TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
TXG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TXG has been increased compared to 5 years ago.
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 3.35 indicates that TXG is not in any danger for bankruptcy at the moment.
The Altman-Z score of TXG (3.35) is better than 60.71% of its industry peers.
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.35 |
ROIC/WACCN/A
WACC10.85%
2.3 Liquidity
TXG has a Current Ratio of 4.90. This indicates that TXG is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.90, TXG is doing good in the industry, outperforming 75.00% of the companies in the same industry.
TXG has a Quick Ratio of 4.12. This indicates that TXG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.12, TXG is in the better half of the industry, outperforming 69.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.12 |
3. Growth
3.1 Past
TXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.90%, which is quite good.
TXG shows a small growth in Revenue. In the last year, the Revenue has grown by 6.57%.
TXG shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.43% yearly.
EPS 1Y (TTM)19.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.03%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y27.46%
Revenue growth 5Y33.43%
Sales Q2Q%-1.3%
3.2 Future
Based on estimates for the next years, TXG will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.33% on average per year.
The Revenue is expected to grow by 5.22% on average over the next years.
EPS Next Y33.66%
EPS Next 2Y19.21%
EPS Next 3Y16.92%
EPS Next 5Y17.33%
Revenue Next Year-2.87%
Revenue Next 2Y1.42%
Revenue Next 3Y4.02%
Revenue Next 5Y5.22%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
TXG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TXG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
62.50% of the companies in the same industry are more expensive than TXG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 75.4 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TXG's earnings are expected to grow with 16.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.21%
EPS Next 3Y16.92%
5. Dividend
5.1 Amount
TXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10X GENOMICS INC-CLASS A
NASDAQ:TXG (1/3/2025, 8:07:29 PM)
After market: 15.667 +0.07 (+0.43%)15.6
+1.41 (+9.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.06%
Inst Owner Change-0.11%
Ins Owners1.73%
Ins Owner Change1.01%
Market Cap1.89B
Analysts73.91
Price Target20.6 (32.05%)
Short Float %5.93%
Short Ratio3.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.44%
Min EPS beat(2)13.05%
Max EPS beat(2)33.83%
EPS beat(4)3
Avg EPS beat(4)8.67%
Min EPS beat(4)-13.26%
Max EPS beat(4)33.83%
EPS beat(8)4
Avg EPS beat(8)-3.72%
EPS beat(12)5
Avg EPS beat(12)-13.15%
EPS beat(16)8
Avg EPS beat(16)-99.59%
Revenue beat(2)1
Avg Revenue beat(2)-2.17%
Min Revenue beat(2)-5.35%
Max Revenue beat(2)1%
Revenue beat(4)1
Avg Revenue beat(4)-1.64%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)1%
Revenue beat(8)5
Avg Revenue beat(8)0.68%
Revenue beat(12)7
Avg Revenue beat(12)-0.16%
Revenue beat(16)11
Avg Revenue beat(16)0.86%
PT rev (1m)0%
PT rev (3m)-26.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.19%
EPS NY rev (1m)-1.21%
EPS NY rev (3m)-5.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3 | ||
| P/FCF | 75.4 | ||
| P/OCF | 48.2 | ||
| P/B | 2.61 | ||
| P/tB | 2.69 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)0.21
FCFY1.33%
OCF(TTM)0.32
OCFY2.07%
SpS5.2
BVpS5.97
TBVpS5.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.47% | ||
| ROE | -25.26% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.63% | ||
| FCFM | 3.98% |
ROA(3y)-16.09%
ROA(5y)-22.37%
ROE(3y)-20.72%
ROE(5y)-28.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.32%
GM growth 5Y-3.84%
F-Score5
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 38.36% | ||
| Cap/Sales | 2.24% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.12 | ||
| Altman-Z | 3.35 |
F-Score5
WACC10.85%
ROIC/WACCN/A
Cap/Depr(3y)379.32%
Cap/Depr(5y)403.39%
Cap/Sales(3y)18.05%
Cap/Sales(5y)16.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.03%
EPS Next Y33.66%
EPS Next 2Y19.21%
EPS Next 3Y16.92%
EPS Next 5Y17.33%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y27.46%
Revenue growth 5Y33.43%
Sales Q2Q%-1.3%
Revenue Next Year-2.87%
Revenue Next 2Y1.42%
Revenue Next 3Y4.02%
Revenue Next 5Y5.22%
EBIT growth 1Y25.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.78%
EBIT Next 3Y21.4%
EBIT Next 5Y23.64%
FCF growth 1Y115.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y194.35%
OCF growth 3YN/A
OCF growth 5YN/A